ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Celgene150 enrolled

Overview

To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2. Planned surveillance period 5 years and 6 months

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Lymphoma, T-Cell, Peripheral

Interventions

IstodaxDRUG

Istodax

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: \- Patients who have been diagnosed with relapsed or refractory PTCL who receive Istodax for the first time. Exclusion Criteria: N/A

Locations (1)

Nihon Seimei Hospital

Osaka, Japan

Outcomes

Primary Outcomes

Adverse Events (AEs)

Number of participants with adverse event

Time frame: Up to approximately 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.